title: Antitumor Efficacy of SLPI Promoter-Controlled Expression of Artificial microRNA Targeting EGFR in a Squamous Cell Carcinoma Cell Line.
abstract: The purpose of this study was to develop a recombinant adenovirus with secretory leukoprotease inhibitor (SLPI) promoter-controlled expression for gene therapy of squamous cell carcinoma (SCC). An artificial microRNA targeting epidermal growth factor receptor (EGFR) was designed, and used to construct a replication-defective recombinant adenovirus with SLPI promoter-controlled expression. The silencing efficiency of this vector (Ad-SLPI-EGFRamiR) was detected in Hep-2 cells. Western blotting showed that the expression of 170 kD EGFR was significantly reduced in Hep-2 cells 72 h after infection with Ad-SLPI-EGFRamiR. At a multiplicity of infection (MOI) of 200 pfu/cell, proliferation of Hep-2 cells was highly inhibited by Ad-SLPI-EGFRamiR (inhibition rate: ~70%). The apoptosis rate of Hep-2 cells at 72 h after infection with Ad-SLPI-EGFRamiR at a MOI 35 pfu/cell was 32.8%. The adenovirus constructed was able to specifically inhibit the growth of SCC cells in vitro.
authors.affiliation: Department of Otorhinolaryngology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang Province, 310009, People's Republic of China.
authors.forename: Jia
authors.initials: J
authors.lastname: Chen
authors.affiliation: Department of Otorhinolaryngology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang Province, 310009, People's Republic of China.|Department of Otorhinolaryngology,Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, 310016, People's Republic of China.
authors.forename: Shoude
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Department of Otorhinolaryngology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang Province, 310009, People's Republic of China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Lin
authors.affiliation: Department of Otorhinolaryngology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang Province, 310009, People's Republic of China. yangbb1959@sina.com.
authors.forename: Beibei
authors.initials: B
authors.lastname: Yang
authors.affiliation: Clinical Research Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang Province, 310009, People's Republic of China. caoj@zju.edu.cn.
authors.forename: Jiang
authors.initials: J
authors.lastname: Cao
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D002294:Carcinoma, Squamous Cell; D045744:Cell Line, Tumor; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors; D006801:Humans; D035683:MicroRNAs / Q000096:biosynthesis* / Q000235:genetics; D011401:Promoter Regions, Genetic; D053481:Secretory Leukocyte Peptidase Inhibitor / Q000235:genetics
chemical_list: D035683:MicroRNAs; C506814:SLPI protein, human; D053481:Secretory Leukocyte Peptidase Inhibitor; C512478:EGFR protein, human; D066246:ErbB Receptors
keywords: EGFR; Gene therapy; Recombinant adenovirus; SLPI; microRNA